1
2
3
4
5
6
7
8
9
10
11
12
13 | On September 25, 2025, Licensing Program Analyst (LPA) Samer Haddadin conducted an unannounced visit to the facility to investigate the above allegation. Upon arrival, LPA Haddadin was greeted and granted entry by Johnny Bugeong. The investigation included staff and resident interviews, a review of facility records, and direct observations of the physical plant.LPA reviewed Resident 1’s (R1) medication records. Documentation reflected that R1’s medications were managed by the facility; however, insulin injections were to be self-administered by R1 with staff oversight only. On August 21, 2025, R1’s responsible party provided written instructions in preparation for scheduled lab work, directing that only Lantus insulin was to be administered, and Apidra insulin withheld. LPA verified these instructions through text message correspondence between the responsible party and the facility. {***CONTINUE 9099C***} |